Abstract
In recent years, the Centers for Medicare & Medicaid Services (CMS) has considered allowing greater flexibility in excluding coverage by Medicare Part D for drugs in 6 currently “protected” classes: antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients.1 CMS and insurers have argued that the protected-class policy requiring coverage for essentially all drugs—which does not apply to commercial payers—hinders effective price negotiations by Medicare Part D plans and contributes to rising prescription drug costs.1,2